High-dose-rate interstitial brachytherapy as a suitable option for metastatic extraskeletal myxoid chondrosarcoma – a case report

We report on a patient with metastatic extraskeletal myxoid chondrosarcoma (EMC), who was treated with palliative high-dose-rate (HDR) interstitial brachytherapy (ISBT). The patient was an 87-year-old woman who underwent an amputation for a bulky tumor in her right ankle joint. EMC was histopathologically confirmed. She presented with a large right inguinal lymph node metastasis of EMC 16 months after surgery. Palliative HDR-ISBT (30 Gy/2 fractions in 1 day) for the right inguinal lymph node metastasis was administered to shorten treatment period. Additional HDR-ISBT (30 Gy/2 fractions in 1 day) was administered for the management of subsequent subcutaneous metastasis to the right breast and right popliteal fossa. HDR-ISBT provided significant long-term control of the recurrent tumor in all three sites, without severe acute and late toxicity. Thus, HDR-ISBT regimen of 30 Gy/2 fractions in 1 day can be a suitable option for both palliation and long-term local control for patients with metastatic EMC.

[1]  R. Maestro,et al.  Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management , 2020, Cancers.

[2]  D. Campanacci,et al.  Extraskeletal Myxoid Chondrosarcoma with Molecularly Confirmed Diagnosis: A Multicenter Retrospective Study Within the Italian Sarcoma Group , 2020, Annals of Surgical Oncology.

[3]  P. Terrier,et al.  Extraskeletal Myxoid Chondrosarcoma: Clinical and Molecular Characteristics and Outcomes of Patients Treated at Two Institutions , 2020, Frontiers in Oncology.

[4]  D. Peake,et al.  Radiotherapy for the Palliation of Advanced Sarcomas—The Effectiveness of Radiotherapy in Providing Symptomatic Improvement for Advanced Sarcomas in a Single Centre Cohort , 2019, Healthcare.

[5]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[6]  P Reichardt,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  R. Ownbey,et al.  Benefit of Radiotherapy in Extraskeletal Myxoid Chondrosarcoma: A Propensity Score Weighted Population-based Analysis of the SEER Database , 2016, American journal of clinical oncology.

[8]  B. Corn,et al.  Radiation Therapy for Palliation of Sarcoma Metastases: A Unique and Uniform Hypofractionation Experience , 2010, Sarcoma.

[9]  W. Enneking,et al.  A System for the Surgical Staging of Musculoskeletal Sarcoma , 1980, Clinical orthopaedics and related research.

[10]  S. Stafford Clinical Radiation Oncology , 2001 .

[11]  André M. Oliveira,et al.  Extraskeletal Myxoid Chondrosarcoma , 2001, Clinical orthopaedics and related research.

[12]  M. Zalupski,et al.  High‐grade extraskeletal myxoid chondrosarcoma: a high‐grade epithelioid malignancy , 1999, Histopathology.

[13]  H. Wanebo,et al.  Soft tissue sarcoma. , 1997, Medicine and health, Rhode Island.

[14]  N. Mandahl,et al.  Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma , 1995, International journal of cancer.

[15]  H. Evans,et al.  Extraskeletal myxoid chondrosarcoma. A clinicopathologic study of ten patients with long‐term follow‐up , 1992, Cancer.

[16]  W. Enneking,et al.  A System for the Surgical Staging of Musculoskeletal Sarcoma , 1980, Clinical orthopaedics and related research.

[17]  F. Enzinger,et al.  Extraskeletal myxoid chondrosarcoma. An analysis of 34 cases. , 1972, Human pathology.

[18]  A. Stout,et al.  Chondrosakcoma of the extraskeletal soft tissues , 1953, Cancer.